01.06.2012 | Research Articles
Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study
Erschienen in: Clinical and Translational Oncology | Ausgabe 6/2012
Einloggen, um Zugang zu erhalten